[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
August 13, 2014

Updated Information

Author Affiliations

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2014;312(6):652. doi:10.1001/jama.2014.9686

In the Viewpoint entitled “An HIV Cure: Feasibility, Discovery, and Implementation” published in the July 23/30, 2014, issue of JAMA (2014;312[4]:335-336. doi:10.1001/jama.2014.4754), important information became available after the Viewpoint went to press. In paragraph 7, sentence 4 onward has been updated to read “First, the infant referred to as the ‘Mississippi Baby,’ who was born to an HIV-infected mother who had received neither prenatal nor perinatal ART, began receiving full antiretroviral treatment at age 30 hours. It was later determined that the infant was infected, and ART was continued through age 18 months, at which point the child was lost to follow-up. At age 23 months the child was again seen in clinic and had no detectable virus in the blood, despite not taking ART for the previous 5 months, and had no HIV-specific antibodies. These results persisted for a total of 27 months without therapy. However, at age 46 months, the child experienced unequivocal viral rebound (consecutive plasma viral load measurements of 16 750 HIV RNA copies/mL and 10 564 copies/mL). Although a permanent cure was not achieved, the infant’s early treatment led to a markedly sustained virologic remission. In light of these new findings, researchers must now work to better understand what enabled the child to remain off treatment for more than 2 years without detectable virus or measurable immunologic response and what might be done to extend the period of sustained HIV remission in the absence of ART.” Additionally, one reference was updated, another added, and the references were renumbered accordingly. This article was corrected online.